Veeva Systems is transitioning its core CRM from Salesforce to its own Vault CRM platform, enhancing its cloud offerings for life sciences across development, quality, commercial, and data workflows. This shift aims to solidify Veeva’s position as a central partner for large biopharma companies, with over 125 clients, including all top 20 global biopharmas, already utilizing Vault CRM. While the move indicates strong adoption, risks remain if large customers hesitate to migrate, which could impact growth forecasts. Analysts project Veeva could reach $4.6 billion in revenue and $1.4 billion in earnings by 2029, presenting a potential 61% upside in stock value. Investors are encouraged to investigate Veeva’s performance and future prospects in depth.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/healthcare/nyse-veev/veeva-systems/news/is-veeva-systems-veev-vault-crm-shift-quietly-redefining-its
